Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From argenx N.V.

Genmab On The Hunt For Late-Stage Assets

The Danish biotech has dipped its toe into co-commercialization recently and is seeking more candidates that are getting closer to the market.

Sales & Earnings M & A

J&J Gets Two Studies Closer To $5bn Sales Goal For Nipocalimab

Analysts said full data from the VIVACITY study in generalized myasthenia gravis would be key to determining the drug’s competitive profile against approved anti-FcRn agents.

Clinical Trials Business Strategies

Stock Watch: Too Early To Call The End Of Biotech Wilderness

To emerge from a wilderness period or biotech winter where generalist investors shun the sector, biotech’s good news needs to outweigh the bad and be attractively priced. We may not be there yet.

Stock Watch Commercial

Takeda Gets FDA Nod For HyQvia In CIDP

The drug could become competitive with Argenx’s Vyvgart Hytrulo, but the market opportunity for the rare disease remains unclear due to continued diagnostic challenges.

Approvals Rare Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • arGEN-X N.V.
UsernamePublicRestriction

Register